Medically reviewed by Arno Kroner, DAOM Key Takeaways Early studies suggest berberine may reduce kidney inflammation, oxidative stress, and scarring, but most evidence comes from animal or lab ...
Picture the cruise ship hospital: gleaming operating rooms, a full pharmacy, a specialist for every ailment. Now picture what’s actually down there. Ships have a medical center, also called an ...
A preclinical mouse study found that intraperitoneally delivered macrophages engineered to secrete IL-10 reduced disease ...
Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use ...
Medically reviewed by Erika Prouty, PharmD Key Takeaways Zinc supports processes involved in blood vessel relaxation, ...
Petrelintide, an amylin agonist medication, may support weight loss with fewer gastrointestinal side effects than GLP-1 drugs, according to early research.
Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in ...
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated ...